Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 3 | 0 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 4 | 1 | 5 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 3 | 2 | 5 |
| 2016 | 5 | 3 | 8 |
| 2017 | 2 | 3 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 4 | 7 |
| 2020 | 4 | 4 | 8 |
| 2021 | 1 | 8 | 9 |
| 2022 | 1 | 8 | 9 |
| 2023 | 1 | 7 | 8 |
| 2024 | 1 | 4 | 5 |
| 2025 | 2 | 1 | 3 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
-
Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
-
Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021 09 27; 36(10):1893-1899.
-
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis. Am J Ther. 2020 Dec 28; 29(1):e74-e84.
-
Establishing Baseline Metrics of Heart Failure Medication Use in Children: A Collaborative Effort from the ACTION Network. Pediatr Cardiol. 2021 Feb; 42(2):315-323.
-
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
-
Preventing a first episode of esophageal variceal hemorrhage. Cleve Clin J Med. 2008 Mar; 75(3):235-44.
-
Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci. 2003 Jun 15; 23(12):5041-9.
-
Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol. 2001 May; 12(5):941-948.
-
Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Physicians. 1999 Jul-Aug; 111(4):357-64.